At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
RC48-ADCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
In Brief
A Phase 1 clinical trial evaluating RC48-ADC for Solid Tumors. Completed, enrolled 24 participants across 1 site.
Detailed Summary
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedAug 2016
Primary CompletionApr 2020
Study CompletionJul 2020
TodayJul 2026
First PostedAug 26, 2016
Enrollment StartMar 1, 2016
Primary CompletionApr 30, 2020
Study CompletionJul 15, 2020
TodayJul 1, 2026
Enrollment to primary: 4.2 yearsPosted 9.8 years ago
Interventions
RC48-ADCdrug